{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:51Z","timestamp":1707525651233},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"DOI":"10.7759\/cureus.51244","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T22:08:36Z","timestamp":1703801316000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in COVID-19 Patients With Pre-existing Cardiac Comorbidities: A Literature Review"],"prefix":"10.7759","author":[{"given":"Sandhya","family":"Srinivasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anam","family":"Dharani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Kalidas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Slater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Mifflin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Physiology, Renin Angiotensin System","author":"Fountain JH","year":"2023","unstructured":"Fountain JH, Jasleen K, Lappin SL. Physiology, Renin Angiotensin System. StatPearls, Treasure Island; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57278","article-title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","volume":"9","author":"Rossi GP","year":"2020","unstructured":"Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020, 9:e57278. 10.7554\/eLife.57278","journal-title":"Elife"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario CM","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, et al.. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005, 111:2605-10. 10.1161\/CIRCULATIONAHA.104.510461","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107628","article-title":"Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities","volume":"215","author":"Wang JJ","year":"2020","unstructured":"Wang JJ, Edin ML, Zeldin DC, Li C, Wang DW, Chen C. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Pharmacol Ther. 2020, 215:107628. 10.1016\/j.pharmthera.2020.107628","journal-title":"Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000174558","article-title":"ACE inhibitors in congestive heart failure","volume":"76","author":"Riegger AJ","year":"1989","unstructured":"Riegger AJ. ACE inhibitors in congestive heart failure. Cardiology. 1989, 76:42-9. 10.1159\/000174558","journal-title":"Cardiology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01229-3","article-title":"A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients","volume":"37","author":"Khalil ME","year":"2001","unstructured":"Khalil ME, Basher AW, Brown EJ, et al.. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001, 37:1757-64. 10.1016\/S0735-1097(01)01229-3","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.06.026","article-title":"COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors","volume":"17","author":"Mitrani RD","year":"2020","unstructured":"Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020, 17:1984-90. 10.1016\/j.hrthm.2020.06.026","journal-title":"Heart Rhythm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104361","article-title":"Sars-CoV-2 and black population: ACE2 as shield or blade?","volume":"84","author":"Vinciguerra M","year":"2020","unstructured":"Vinciguerra M, Greco E. Sars-CoV-2 and black population: ACE2 as shield or blade?. Infect Genet Evol. 2020, 84:104361. 10.1016\/j.meegid.2020.104361","journal-title":"Infect Genet Evol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.3786","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens","volume":"323","author":"Wang W","year":"2020","unstructured":"Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020, 323:1843-4. 10.1001\/jama.2020.3786","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-00450-0","article-title":"Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models","volume":"31","author":"Wang G","year":"2021","unstructured":"Wang G, Yang ML, Duan ZL, et al.. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res. 2021, 31:17-24. 10.1038\/s41422-020-00450-0","journal-title":"Cell Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138080","article-title":"COVID-19 in patients with heart failure: the new and the old epidemic","volume":"97","author":"Sisti N","year":"2021","unstructured":"Sisti N, Valente S, Mandoli GE, et al.. COVID-19 in patients with heart failure: the new and the old epidemic. Postgrad Med J. 2021, 97:175-9. 10.1136\/postgradmedj-2020-138080","journal-title":"Postgrad Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.17.20104943","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19","author":"Khera R","year":"2020","unstructured":"Khera R, Clark C, Lu Y, et al.. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19. medRxiv. 2020, 10.1101\/2020.05.17.20104943","journal-title":"medRxiv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018086","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with COVID-19","volume":"10","author":"Khera R","year":"2021","unstructured":"Khera R, Clark C, Lu Y, et al.. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with COVID-19. J Am Heart Assoc. 2021, 10:e018086. 10.1161\/JAHA.120.018086","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202001-0179LE","article-title":"Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2","volume":"202","author":"Zhao Y","year":"2020","unstructured":"Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020, 202:756-9. 10.1164\/rccm.202001-0179LE","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.03.004","article-title":"Severity of COVID-19 infection in ACEI\/ARB users in specialty hospitals: a retrospective cohort study","volume":"14","author":"Alrashed AA","year":"2021","unstructured":"Alrashed AA, Khan TM, Alhusseini NK, et al.. Severity of COVID-19 infection in ACEI\/ARB users in specialty hospitals: a retrospective cohort study. J Infect Public Health. 2021, 14:726-33. 10.1016\/j.jiph.2021.03.004","journal-title":"J Infect Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151418","article-title":"In-hospital use of ACE inhibitors\/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients","volume":"131","author":"Li S","year":"2021","unstructured":"Li S, Sarangarajan R, Jun T, et al.. In-hospital use of ACE inhibitors\/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. J Clin Invest. 2021, 131:e151418. 10.1172\/JCI151418","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-021-01004-9","article-title":"Colonic epithelial angiotensin-converting enzyme 2 (ACE2) expression in blacks and whites: potential implications for pathogenesis Covid-19 racial disparities","volume":"9","author":"De La Cruz M","year":"2022","unstructured":"De La Cruz M, Nunes DP, Bhardwaj V, Subramanyan D, Zaworski C, Roy P, Roy HK. Colonic epithelial angiotensin-converting enzyme 2 (ACE2) expression in blacks and whites: potential implications for pathogenesis Covid-19 racial disparities. J Racial Ethn Health Disparities. 2022, 9:691-7. 10.1007\/s40615-021-01004-9","journal-title":"J Racial Ethn Health Disparities"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-0691-z","article-title":"ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population","volume":"28","author":"Benetti E","year":"2020","unstructured":"Benetti E, Tita R, Spiga O, et al.. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. Eur J Hum Genet. 2020, 28:1602-14. 10.1038\/s41431-020-0691-z","journal-title":"Eur J Hum Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein R","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, Gr\u00e4ni C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?. J Am Heart Assoc. 2020, 9:e016509. 10.1161\/JAHA.120.016509","journal-title":"J Am Heart Assoc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo T","year":"2020","unstructured":"Guo T, Fan Y, Chen M, et al.. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020, 5:811-8. 10.1001\/jamacardio.2020.1017","journal-title":"JAMA Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01291-4","article-title":"Outcomes in patients with COVID-19 infection taking ACEI\/ARB","volume":"22","author":"Rico-Mesa JS","year":"2020","unstructured":"Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI\/ARB. Curr Cardiol Rep. 2020, 22:31. 10.1007\/s11886-020-01291-4","journal-title":"Curr Cardiol Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.04.037","article-title":"Debate on drugs that may aggravate COVID-19","volume":"8","author":"Giavina-Bianchi P","year":"2020","unstructured":"Giavina-Bianchi P, Aun MV, Agondi RC, Kalil J. Debate on drugs that may aggravate COVID-19. J Allergy Clin Immunol Pract. 2020, 8:2452-3. 10.1016\/j.jaip.2020.04.037","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref23","unstructured":"Efficacy of captopril in Covid-19 patients with severe acute respiratory syndrome (SARS) COV-2 pneumonia (CAPTOCOVID). (2020). Accessed. July 8, 2023: https:\/\/clinicaltrials.gov\/study\/NCT04355429."},{"key":"ref24","unstructured":"Efficacy of aerosol combination therapy of 13 cis retinoic acid and captopril for treating Covid-19 patients via indirect inhibition of transmembrane protease (TMPRSS2). (2020). Accessed. July 8, 2023: https:\/\/clinicaltrials.gov\/study\/NCT04578236."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14329","article-title":"Influence of angiotensin converting enzyme inhibitors\/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: a systemic review and meta-analysis","volume":"23","author":"Jia N","year":"2021","unstructured":"Jia N, Zhang G, Sun X, et al.. Influence of angiotensin converting enzyme inhibitors\/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: a systemic review and meta-analysis. J Clin Hypertens. 2021, 23:1651-63. 10.1111\/jch.14329","journal-title":"J Clin Hypertens"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14473","article-title":"Temporal variation, socioeconomic status, and out-of-hospital deaths as factors that influence mortality rates among hospitalized COVID-19 patients receiving ACEIs\/ARBs","volume":"24","author":"Aftab OM","year":"2022","unstructured":"Aftab OM, Modak A, Patel JC. Temporal variation, socioeconomic status, and out-of-hospital deaths as factors that influence mortality rates among hospitalized COVID-19 patients receiving ACEIs\/ARBs. J Clin Hypertens. 2022, 24:519-20. 10.1111\/jch.14473","journal-title":"J Clin Hypertens"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/164670-clinical-outcomes-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-in-covid-19-patients-with-pre-existing-cardiac-comorbidities-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:46Z","timestamp":1707509506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/164670-clinical-outcomes-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-in-covid-19-patients-with-pre-existing-cardiac-comorbidities-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.51244","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}